Amarin Says Partner EddingPharm Receives Regulatory Approval For Vascepa (Icosapent Ethyl) In Mainland China
Portfolio Pulse from Benzinga Newsdesk
Amarin's partner EddingPharm has received regulatory approval for Vascepa (Icosapent Ethyl) in mainland China. This approval will allow the drug to be marketed and sold in the region.
June 01, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amarin's stock may see a positive short-term impact as its partner EddingPharm receives regulatory approval for Vascepa in mainland China, expanding the drug's market.
The regulatory approval for Vascepa in mainland China will allow Amarin's partner EddingPharm to market and sell the drug in the region. This expansion into a new market has the potential to increase Amarin's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100